Xanthostat Diagnostics Inc. was founded in 2005 based on proof of concept results generated by the founders, professor Joe Clark, professor Fred Beyette, and Chad Morgan, in their University of Cincinnati research labs. The A patent on the core technology was issued to the University of Cincinnati in the Fall of 2011. Since founding the company, the management team which includes expertise in biomedical engineering, biomedical research science, and clinical practice, has brought on investors and board members with experience in business management and medical product commercialization.
Xanthostat and their development team, led by Beyette, have successfully transitioned the technology from a research proof-of-concept, to a functional prototype. This prototype is well positioned to bring this innovative technology into the biomedical device market place. The device is intended to be used by doctors to help save the lives of patients suffering from SAH.
Beyette and Xanthostat Diagnostics Inc. are finalists in the Outstanding Bioscience Innovation Award category. The winning nominee is a company with fewer than 50 employees that has achieved a significant milestone in the life sciences, including but not limited to drug therapeutics, medical devices, medical imaging and pharmacogenetics.
This is the 2nd annual Cincinnati USA Innovation Awards. The Innovation Awards celebrate innovative companies and people that show how new ideas can be developed into fuel for the Tri-State’s economic engine. The program is being presented by the Business Courier and Cincinnati USA Regional Chamber and Community Partner, CincyTech. The winners will be announced at an event on April 17, 2012 and will be featured in the April 20th Business Courier print edition.